Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Prometic Presents Positive Results for PBI-4050 in Liver Fibrosis

Published: Monday, November 04, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
ProMetic Life Sciences Inc. presented new preclinical data at the 2013 annual meeting of the American Association for the Study of Liver Diseases (AASLD).

Results support the claims that PBI-4050 anti-fibrotic activity could also be used to address various liver conditions such as nonalcoholic steatohepatitis ("NASH"), a condition affecting 2% to 5% of Americans.

PBI-4050's favorable effect in reducing the progression of fibrosis in liver was demonstrated in two different "gold-standard" animal models.  The first is a diabetic mouse model in which the animals develop liversteatosis.  Similar to what is observed in humans, the untreated animals accumulate fat in the liver causing inflammation and leading to permanent damage and scarring, and reducing the ability for the liver to function properly. Diabetic mice treated with PBI-4050 had a significant reduction of liver lesions and steatosis measured by histology as well as a significant reduction in key biomarkers such as including TGFβ-1, Collagen 1, MMP2 and TIMP-1.

In a second model, the liver fibrosis is induced by chronic administration of carbon tetrachloride (CCL4), a chemical which at high chronic dose, causes irreversible damage to the liver and the kidney.  Again animals treated with PBI-4050 displayed a significant reduction of liver lesions as evidenced by histology and relevant biomarkers.

"These results clearly indicates that PBI-4050 anti-fibrotic activity is at the core of the fibrosis regulation pathway affecting multiple organs and tissues", stated Dr. Lyne Gagnon, Head of Biology & Immunology at ProMetic.

Dr. John Moran, a member of ProMetic's Board of Directors stated "Since patients with diabetes are more likely to develop complications affecting the kidneys and liver, the positive effects observed with PBI-4050 in multiple challenging animal models bodes well for its potential use in this patient population."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Prometic to Acquire Telesta
Prometic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction.
Thursday, August 25, 2016
ProMetic and Sartorius Stedim Biotech Join Forces
ProMetic BioProduction's plasma purification facility to become the technological showroom for Plasma Protein Purification System, SSB to contribute equipment and consumables.
Wednesday, May 01, 2013
ProMetic Receives $4.6 Million Purchase Order from Octapharma
Purchase order triggers $1.1 million upfront payment.
Wednesday, June 27, 2012
ProMetic Achieves Pivotal Milestone for Its Plasma-Derived Therapeutics Business
Facility to scale-up ProMetic's proven manufacturing technology for PPPS™ with a targeted capacity of 150,000 liters of plasma annually.
Wednesday, February 09, 2011
ProMetic Announces Signature of Definitive License Agreement with Kedrion
Kedrion has in-licensed ProMetic's yield improving technology.
Thursday, February 28, 2008
Prometic Mimetic Ligand™ Adsorbent Successfully Implemented In Large-Scale Biomanufacturing Process
Approximately 800 liters of a commercial Mimetic Ligand™ product were packed and successfully operated in a 1.8 meter diameter process chromatography column.
Thursday, September 20, 2007
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos